Abstract
The overexpression of the oncogene Her2/neu (Her2) is a negative prognostic factor for relapse free survival in breast cancer and may be associated with a poorer response to hormonal therapy compared to Her2 negative patients. This study was undertaken to determine whether the overexpression of Her2 has any impact upon the local recurrence in women with early stage breast cancer treated with breast conservation therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation OncologyBiologyPhysics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
